Details of the Drug

General Information of Drug (ID: DM1NOEK)

Drug Name
Metreleptin
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1], [2]
Sequence
MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLA
VYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGY
STEVVALSRLQGSLQDMLWQLDLSPGC
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 3.8 - 4.7 hours [3]
Metabolism
The drug is metabolized via renal [4]
Vd
The volume of distribution (Vd) of drug is 0.37 L/kg [5]
Cross-matching ID
DrugBank ID
DB09046
TTD ID
D0Z9EO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leptin receptor (LEPR) TT0HD6V LEPR_HUMAN Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leptin receptor (LEPR) DTT LEPR 5.82E-02 0.05 0.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Metreleptin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Increased metabolism of Metreleptin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [8]
Ivabradine DM0L594 Moderate Increased metabolism of Metreleptin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [9]
LY2835219 DM93VBZ Moderate Increased metabolism of Metreleptin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [10]
Tucatinib DMBESUA Moderate Increased metabolism of Metreleptin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Palbociclib DMD7L94 Moderate Increased metabolism of Metreleptin caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Alpelisib DMEXMYK Moderate Increased metabolism of Metreleptin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
PF-04449913 DMSB068 Moderate Increased metabolism of Metreleptin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [14]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Metreleptin caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [15]
Oestradiol valerate and dienogest DMZK0FQ Moderate Decreased metabolism of Metreleptin caused by Oestradiol valerate and dienogest mediated inhibition of CYP450 enzyme. Endometriosis [GA10] [16]
Tazemetostat DMWP1BH Moderate Increased metabolism of Metreleptin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [17]
Ripretinib DM958QB Moderate Increased metabolism of Metreleptin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Avapritinib DMK2GZX Moderate Increased metabolism of Metreleptin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [9]
MK-1439 DM215WE Moderate Increased metabolism of Metreleptin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Fostemsavir DM50ILT Minor Increased metabolism of Metreleptin caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Naloxegol DML0B41 Moderate Increased metabolism of Metreleptin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [20]
Pemigatinib DM819JF Moderate Increased metabolism of Metreleptin caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [9]
Brigatinib DM7W94S Moderate Increased metabolism of Metreleptin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Ceritinib DMB920Z Moderate Increased metabolism of Metreleptin caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [21]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Metreleptin caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Osimertinib DMRJLAT Moderate Increased metabolism of Metreleptin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [23]
Capmatinib DMYCXKL Moderate Increased metabolism of Metreleptin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [24]
Selpercatinib DMZR15V Moderate Increased metabolism of Metreleptin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [9]
Idelalisib DM602WT Moderate Increased metabolism of Metreleptin caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
GDC-0199 DMH0QKA Moderate Increased metabolism of Metreleptin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [26]
IPI-145 DMWA24P Moderate Increased metabolism of Metreleptin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [27]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Metreleptin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [28]
Selumetinib DMC7W6R Moderate Increased metabolism of Metreleptin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [29]
LGX818 DMNQXV8 Moderate Increased metabolism of Metreleptin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [30]
Ubrogepant DM749I3 Moderate Increased metabolism of Metreleptin caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [31]
Rolapitant DM8XP26 Moderate Increased metabolism of Metreleptin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [32]
Entrectinib DMMPTLH Moderate Increased metabolism of Metreleptin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [33]
Olaparib DM8QB1D Moderate Increased metabolism of Metreleptin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [12]
Macimorelin DMQYJIR Moderate Increased metabolism of Metreleptin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [34]
LDE225 DMM9F25 Moderate Increased metabolism of Metreleptin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [35]
LEE011 DMMX75K Moderate Increased metabolism of Metreleptin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Fostamatinib DM6AUHV Moderate Increased metabolism of Metreleptin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [36]
⏷ Show the Full List of 36 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7333).
2 US FDA approves orphan drug MYALEPT (metreleptin for injection)
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
8 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
11 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
14 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
15 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
16 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
17 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
18 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
19 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
20 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
21 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
23 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
26 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
27 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
28 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
29 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
31 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
32 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
33 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
34 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
35 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.